« Return to News | CROs/Service Providers

Protagen, Charles River form marketing alliance

Friday, October 28, 2011 10:39 AM

Protagen and Charles River Laboratories International have formed a strategic marketing & sales alliance.

For Charles River the fast-growing demand for biopharmaceuticals testing requires an expert partner with a broad range of services. Charles River delivers client-focused solutions tailored to the specific testing and manufacturing requirements of biologics. Partnering with Protagen, a specialist in the fields of in-vitro diagnostics and GMP-compliant protein analysis, will provide clients with services covering the entire range of protein analytics from detailed protein characterization to stability and lot release testing.

Working together, Charles River and Protagen can offer analytical experience and superior services through a single point of contact, providing more efficient project work and study design.

“The technology portfolio and the exceptional expertise of Charles River in the area of certified bioservices will synergistically complement the experience and competences of Protagen in the field of biotherapeutics and biosimilars. The customers in the pharmaceutical and biotech sector will profit from this alliance through the direct access to a comprehensive service portfolio,” said Dr. Stefan Müllner, CEO of Protagen.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.